Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation

The blockade of immune checkpoints, such as programmed death receptor 1 (PD-1) and programmed death ligand 1 protein (PD-L1), is a promising therapeutic approach in cancer immunotherapy. Nivolumab, a humanized IgG4 antibody targeting PD-1, was approved by the US Food and Drug Administration for seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenping, Jin, Haoyu, Chen, Ting, Zhang, Gangping, Lai, Shengsheng, Liu, Guangjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522605/
https://www.ncbi.nlm.nih.gov/pubmed/33102523
http://dx.doi.org/10.3389/fmolb.2020.574759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522605/
https://www.ncbi.nlm.nih.gov/pubmed/33102523
http://dx.doi.org/10.3389/fmolb.2020.574759

Ejemplares similares